A5000178052- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Sarcoma Diagnosis and Treatment
- Bartonella species infections research
- Cancer Cells and Metastasis
- Medical Imaging and Pathology Studies
- Glycosylation and Glycoproteins Research
- Herpesvirus Infections and Treatments
- Hepatitis B Virus Studies
- HER2/EGFR in Cancer Research
- Radiopharmaceutical Chemistry and Applications
- Pancreatic and Hepatic Oncology Research
AstraZeneca (United Kingdom)
2017-2023
Programmed cell death ligand-1 (PD-L1) expression levels in patient tumor samples have proven clinical utility across various cancer types. Several independently developed PD-L1 immunohistochemical (IHC) predictive assays are commercially available. Published studies using the VENTANA (SP263) Assay, (SP142) Dako IHC 22C3 pharmDx assay, 28-8 and laboratory-developed tests utilizing E1L3N antibody (Cell Signaling Technology), demonstrated differing of staining between assays, resulting...
Several anti-programmed cell death-1 (PD-1) and death ligand-1 (PD-L1) therapies have shown encouraging safety clinical activity in a variety of tumor types. A potential role for PD-L1 testing identifying patients that are more likely to respond treatment is emerging. expression practice determined by one section per patient. Therefore, it critical understand the impact tissue sampling variability on patients’ classification. Resected non-small lung cancer (NSCLC), head neck squamous...
e14502 Background: Clinical assessment of PD-L1 status relies on the result testing 1 FFPE section per patient (pt). Heterogeneity expression within a single tissue block and between paired blocks from same pt could impact classification. This study characterizes intra-block intra-case heterogeneity using VENTANA (SP263) Assay in non-small cell lung cancer (NSCLC), head neck squamous carcinoma (HNSCC) urothelial (UC) for tumor (TC) immune (IC) staining. Methods: Two 5 cases each 3...